Current studies evaluating the efficacy and safety of lipid-targeted therapies to reduce cardiovascular events are being performed on the background of statin therapy, given the overwhelming evidence from numerous randomized clinical studies indicating a reduction of occlusive vascular events by statin therapy (1) .
Niacin -a lipid-modifying agent with a long history: Already in 1955 Dr Altschul and colleagues described that high-doses of the vitamin B 3 (niacin) reduced serum cholesterollevels ( Figure 1 ) (2) . Later, the Coronary Drug Project (CDP) sponsored by the National Heart and Lung Institute (published in 1975) tested the efficacy and safety of long-term therapy with a high dose of niacin (3 g/day) in men after myocardial infarction (3) . In the CDP there was no significant effect of niacin therapy on the primary end point, i.e. all-cause mortality, but a significant reduction in the rate of recurrent non-fatal myocardial infarction by 27 % was observed (3). The authors concluded that the "Coronary Drug Project data yield no evidence that niacin influences mortality of survivors of myocardial infarction; this medication may be slightly beneficial in protecting persons to some degree against recurrent nonfatal myocardial infarction", that is to say that the authors were not overly enthusiastic with respect to the efficacy of the compound to prevent major cardiovascular events.
Already in this early study it became apparent that the adherence to niacin therapy was significantly reduced as compared to placebo, likely due to the well-known skin and gastrointestinal side effects of the compound (3). Impact on Global Health Outcomes trial (AIM-HIGH) was aiming to evaluate the impact of raising HDL-cholesterol levels with niacin therapy (1.5-2 g/day) on cardiovascular events in subjects with similar LDL cholesterol levels (achieved by higher statin doses and ezetimibe therapy in the comparator treatment arm) (11) . In this study the primary end point, a composite of the first event of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptomdriven coronary or cerebral revascularization, was not reached by niacin therapy in patients with established cardiovascular disease and an atherogenic dyslipidemia (11) . In fact, the trial was stopped early because the boundary for futility had been crossed and a higher number of ischemic strokes was observed in patients assigned to niacin (11) . However, the interpretation of the results of the trial with respect to niacin has been somewhat difficult due to the design, i.e. the fact that more placebo-treated patients required increases in the statin patients with pre-existing occlusive vascular disease (10) . The sponsor of the trial has recently communicated that the study did not meet its primary endpoint of reduction of major vascular events, although the detailed data presentation is still expected. Within this largescale clinical study, a careful analysis of the side effects was pre-specified, in particular with respect to muscle and liver outcomes and reasons for stopping study treatment that is reported in the current issue of the European Heart Journal. The addition of ER-niacin/laropiprant to 40 mg simvastatin therapy (and ezetimibe in some participants) increased the risk of definite myopathy. The risk of myopathy on the combination therapy was substantially more pronounced in Chinese patients as compared to Europe, indicating that the safety of a drug in one region and in Caucasians cannot necessarily be translated to other regions, such as Asia Interestingly, a recent experimental study has observed that prostaglandin D(2) receptor-1 deletion in mice augmented aneurysm formation and accelerated atherogenesis and thrombogenesis, and these authors suggested that niacin-induced PGD₂ release may function as a constraint on platelets during niacin therapy (16) . The effects of inhibition of the PG-D(2) receptor-1 by laropiprant on thrombosis and atherosclerosis in humans in vivo are likely difficult to predict and complex, since it has been observed that on the one hand laropiprant at low concentrations prevented the inhibitory effects of PGD 2 on platelet function, including effects on platelet aggregation and thrombus formation, but on the other hand laropiprant at higher concentrations attenuated platelet activation induced by thromboxane and inhibited thrombus formation (17) . Similarly, the effects of prostaglandin D(2) receptor-1 inhibition on atherosclerotic plaque formation in mouse models have not been consistent, with accelerated atherosclerosis in some, but not all atherosclerotic mouse models (18) . Disclosure: U.L. has received speaker fees or research grants from Merck, Roche and Pfizer.
